CONFERENCE DIRECTORS

Helen K. Chew, M.D.
Professor of Medicine
Division of Hematology and Oncology
Department of Internal Medicine
UC Davis School of Medicine

Scott Chistensen, M.D.
Professor of Medicine
Division of Hematology and Oncology
Department of Internal Medicine
UC Davis Comprehensive Cancer Center

Primo Lara, Jr., M.D.
Professor of Medicine
Division of Hematology and Oncology
Department of Internal Medicine
UC Davis School of Medicine

PRESENTED BY

SPONSORED BY:
THE MEDICAL EDUCATOR CONSORTIUM
The 17th Annual Advances in Oncology program will bring together academic and community oncologists for the purpose of educating participants on the state-of-the-art clinical management of a wide variety of solid and hematologic malignancies. The program is designed to update physicians and other cancer healthcare providers on recent advances and new diagnostic and treatment modalities in hematologic, breast, lung, gastrointestinal, and genitourinary cancers. This course is intended for physicians and cancer health care providers, including medical, surgical and radiation oncologists, nurses, physician assistants, pharmacists and other interested health care professionals. The conference includes didactic sessions from national oncology leaders and case-based panel discussions involving academic and community oncologists.

EDUCATIONAL OBJECTIVES

At the conclusion of this symposium, you should be able to:
1. Discuss advances in prognostic and predictive biomarkers and potential applications in therapeutic decision making.
2. Integrate targeted and traditional therapeutic modalities in the treatment of cancer.
3. Assess newly validated treatment options for patients with solid tumors or hematologic malignancies.
4. Apply data from recent clinical trials to determine the optimal course of therapy in defined patient populations, with emphasis on novel agents including mTOR inhibitors, ALK inhibitors, monoclonal antibodies, multi-targeted tyrosine kinase inhibitors, and inhibitors of cyclin kinase 4 and 6, among others.

NEEDS ASSESSMENT

The diagnosis, risk stratification, and multi-modality state-of-the-art treatment of hematologic and solid malignancies are rapidly evolving. The development of molecular prognostic assays and novel targeted therapies provides promising tools for personalized medicine.

As a result of prior course participant evaluations and needs assessment surveys, the need for cutting edge information on prognostic markers and appropriate application of novel therapies has been identified. This year's conference will specifically address these needs in the common malignancies identified by past participants as essential to their practice, including solid and hematologic cancers. The timing of this meeting in the fall allows for the latest findings in clinical cancer research from major hematology and oncology conferences to be presented and discussed. This educational activity also meets a unique need for the Northern California Sacramento Valley to provide a group of networked and collaborating oncologists a forum to discuss the most recent developments in oncology care in the context of local treatment approaches, patient populations, and open clinical trials.

The course is designed to change physician competence in oncology care. State of the art lectures and panel discussions from local and national oncologists will provide ample discussions on the applications and challenges of new prognostic tools and targeted and cytotoxic therapies. Pre-lecture and post-lecture audience response systems (evaluations) will be used in outcome measures.

ACCREDITATION

The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT HOURS

The Medical Educator Consortium designates this live activity for a maximum of 8.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURE

The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

NURSING CONTINUING MEDICAL EDUCATION

Continuing Medical Education is acceptable for meeting RN continuing education requirements, as long as the course is AMA PRA Category 1 Credits™, and has been taken within the appropriate time frames.
Mehrdad Abedi, M.D.
Associate Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Theresa R. Arciniega, LCSW
Chief Licensed Clinical Social Worker
Department of Clinical Social Services
UC. Davis Health System

Mili Arora, M.D.
Assistant Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Kristie Bobolis, M.D.
Medical Oncologist
Capitol Hematology-Oncology

Helen K. Chew, M.D.
Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Scott Christensen, M.D.
Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

David Cooke, M.D.
Assistant Professor
Assoc. Program Director, Cardiothoracic
Surgery Residency
Division of Cardiothoracic Surgery
UC Davis Medical Center

Megan Daly, M.D.
Assistant Professor
Department of Radiation Oncology
UC Davis Comprehensive Cancer Center

David Gandara, M.D.
Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Brian Jonas, M.D., Ph.D.
Assistant Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Melissa Kaimo, M.D.
Medical Oncology
Gene Upshaw Memorial Tahoe Forest Cancer Center

Hagop Kantarjian, M.D.
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center

Primo N. Lara, Jr., M.D.
Professor of Medicine
Division of Hematology and Oncology
Associate Director for Translational Research
UC Davis Comprehensive Cancer Center

Benjamin Leavy, M.D.
Associate Physician
Family and Community Medicine
UC Davis Medical Group

Anna Orlowski, JD
Chief Health System Counsel
UC Davis Health System

Chong-Xian Pan, M.D.
Associate Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Ajithkumar Puthillath, M.D.
Hematologist-Oncologist
Stockton Hematology Oncology

Jonathan Riess, M.D.
Assistant Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Eve Rodler, M.D.
Assistant Adjunct Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Aaron Rosenberg, M.D.
Assistant Professor
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Philip Sardar, M.D.
Hematologist/Oncologist
Kaiser Permanente

Candice Sauder, M.D.
Assistant Professor of Surgery
Division of Surgical Oncology
UC Davis Comprehensive Cancer Center

Thomas Semrad, M.D.
Medical Oncology
Gene Upshaw Memorial Tahoe Forest Cancer Center

Samer Shihabi, M.D.
Hematologist-Oncologist
Mercy Medical Group

Sandy Srinivas, M.D.
Associate Professor of Medicine
Stanford University

Joseph Tuscano, M.D.
Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center

Richard Valicenti, M.D.
Professor and Chair
Department of Radiation Oncology
UC Davis Comprehensive Cancer Center

Stanley Yap, M.D.
Assistant Professor
Department of Urology
UC Davis Comprehensive Cancer Center
**AGENDA**

**FRIDAY, SEPTEMBER 30TH** *(FRIDAY ONLY at Cancer Center Auditorium UC Davis Comprehensive Cancer Center - no exhibits available on this day)*

12:30 pm
Welcome Lunch

1:00 pm
Introduction of Keynote Speaker: The Lois O’Grady Lectureship
(Presentation of award to Dr. Hagop Kantarjian) 
Ted Wun, M.D.

1:10 pm
O’Grady Keynote Lecture: Dr. Hagop Kantarjian

1:55 pm
Question and Answer session

2:00 pm
Chronic Lymphocytic Leukemia: Novel Therapeutics
Joseph Tuscano, M.D.

2:20 pm
Multiple Myeloma: What are the Optimal Therapies in 2016?
Aaron Rosenberg, M.D.

2:40 pm
Update on Cellular Therapies for Hematologic Malignancies
Mehrdad Abedi, M.D.

3:00 pm
Panel Discussion: Practice Changing Developments in Benign and Malignant Hematology
Moderator: Brian Jonas, M.D.
Panel: Mehrdad Abedi, M.D., Hagop Kantarjian, M.D., Ajithkumar Puthillath, M.D., Aaron Rosenberg, M.D., Joseph Tuscano, M.D.

3:30 pm
Q&A (Interactive Audience Participation): Benign and Malignant Hematology
Anna Orlowski, JD

3:55 pm
End of Life Option Act: Medical Legal Considerations
Scott Christensen, M.D.

4:15 pm
Adjourn for the day

**SATURDAY, OCTOBER 1ST** *(SATURDAY ONLY at the Hyatt Regency Sacramento – exhibits welcomed)*

7:00 am
Registration, Coffee, Visit Exhibits

7:15 am
Breakfast & Learn Symposia (non cme)

8:30 am
Welcome Remarks
Primo N. Lara, Jr., M.D. and Helen K. Chew, M.D.

8:35 am
Pre-session Survey
Scott Christensen, M.D.

8:40 am
Keynote Lecture #1: The Lois O’Grady Lectureship
“Molecular Targets of Interest in Acute Leukemias”
Hagop Kantarjian, M.D.

9:20 am
State of the Art in Genitourinary Cancers
Sandy Srinivas, M.D.

9:40 am
Panel Discussion: Challenging Cases in Genitourinary Cancers
Moderator: Stanley Yap, M.D.
Panel: Primo Lara, M.D., Chong-Xian Pan, M.D., Philip Sardar, M.D., Samer Shihabi, M.D., Richard Valicenti, M.D.

10:10 am
Q&A (Interactive Audience Participation): Genitourinary Cancers

10:15 am
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings
Eve Rodler, M.D.

10:35 am
Panel Discussion: Optimal Therapies in Breast Cancer
Moderator: Helen Chew, M.D.
Panel: Mili Arora, M.D., Kristie Bobolis, M.D., Candice Sauder, M.D., Scott Christensen, M.D., Melissa Kaline, M.D., Eve Rodler, M.D.

11:05 am
Q&A (Interactive Audience Participation): Breast Cancer

11:10 am
Visit Exhibits

11:20 am
Lunch & Learn Symposia (non CME)

12:20 pm
Coffee & Visit Exhibit

12:40 pm
New Developments in Lung Cancer Therapeutics
David Gandara, M.D.

1:00 pm
Panel Discussion: Translating Results of Trials in Small Cell and Non-Small Cell Lung Cancer into Clinical Practice
Moderator: Jonathan Riess, M.D.
Panel: David Cooke, M.D., Megan Daly, M.D., David Gandara, M.D., Samer Shihabi, M.D.

1:30 pm
Q&A (Interactive Audience Participation): Lung Cancer

1:35 pm
Advances in Gastrointestinal Malignancies
Thomas Semrad, M.D.

1:55 pm
Clinical Updates in Solid Tumor Oncology
Johnathan Riess, M.D.

2:15 pm
Post-session Survey/Closing Remarks: Scott Christensen, M.D.

2:20 pm
Adjourned
Register online at www.meccinc.com
or FAX to 305/675-2718.

Name _____________________________________________ Degree __________________
Address ____________________________________________________________________
City _________________________________ State ___________________ Zip ___________
Telephone (___)___________________________ FAX (____)________________________
Email address _______________________________________________________________
Specialty ___________________________________________________________________

Type of Practice:  □ Private  □ Academic  □ Hospital  □ Resident/Fellow
I will be attending
□ BOTH days September 30 and October 1st
□ ONLY Friday September 30 at the Cancer Center Auditorium UC Davis
Comprehensive Cancer Center
□ ONLY Saturday, October 1st at the Hyatt Regency Sacramento

Registration fee
$150 Physicians
$  75 Nurses, Fellows, Residents and Allied Health Care
$250 Industry Professionals

Refunds must be provided in writing prior to August 15, 2016. After August 15, 2016,
No Refunds will be provided. A $50.00 administrative fee is charged on all refunds.

Enclosed is my check i/a/o of _____ for registration of this course.
I authorize MECC to charge my credit card i/a/o $_______ for registration of this
course using the following credit card.

Name on Card _______________________________________ Exp. Date______________
Card number _______________________________________ CVV Code______________
Authorized signer ___________________________________________________________

CONFERENCE LOCATION
This conference is held at two locations. No transportation will be provided from the
host hotel.

Friday, September 30th
UC Davis Comprehensive Cancer Center
Cancer Center Auditorium
4501 X Street
Sacramento, CA 95817
Parking is available in the lot adjacent to the Cancer Center.

Saturday, October 1st
HYATT REGENCY
1209 L Street
Sacramento, CA 95814

For more information contact:
CONFERENCE MANAGEMENT
MECC 6619 South Dixie Highway, # 341, Miami, FL  33143
Telephone 305/663-1628 Office Fax 305/675-2718
Or visit our website at www.meccinc.com
Email: tvalls@meccinc.com